Login to Your Account

PDL's Buyout Of ESP Pharma: $475M For Drugs, Sales Team

By Randall Osborne

Wednesday, January 26, 2005
Protein Design Labs Inc. agreed to buy the hospital-focused pharmaceutical firm ESP Pharma Inc. for $300 million in cash and about $175 million in stock, thereby gaining marketed products, a 75-person sales force, entry into the cardiac field - and about $14 million in ESP debt. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription